Integra Lifesciences Holdings (IART) Cash & Equivalents (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cash & Equivalents data on file, last reported at $236.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 0.96% year-over-year to $236.8 million; the trailing twelve-month figure through Mar 2026 stood at $236.8 million (down 0.96% YoY), and the FY2025 full-year result was $235.0 million, down 4.6% from the prior year.
• Cash & Equivalents advanced to $236.8 million in Q1 2026, from $235.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $591.9 million in Q1 2024 to a low of $215.2 million in Q3 2024.
• A 5-year average of $318.8 million and a median of $273.7 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 92.57% in 2024 and tumbled 59.61% in 2025, its largest moves.
• Tracing IART's Cash & Equivalents over 5 years: stood at $456.7 million in 2022, then plunged by 39.47% to $276.4 million in 2023, then retreated by 10.86% to $246.4 million in 2024, then declined by 4.6% to $235.0 million in 2025, then gained by 0.75% to $236.8 million in 2026.
• Business Quant data shows IART's Cash & Equivalents at $236.8 million in Q1 2026, $235.0 million in Q4 2025, and $232.2 million in Q3 2025.